EP0386109A1 - Acceleration of bone formation with gm-csf - Google Patents

Acceleration of bone formation with gm-csf

Info

Publication number
EP0386109A1
EP0386109A1 EP88910226A EP88910226A EP0386109A1 EP 0386109 A1 EP0386109 A1 EP 0386109A1 EP 88910226 A EP88910226 A EP 88910226A EP 88910226 A EP88910226 A EP 88910226A EP 0386109 A1 EP0386109 A1 EP 0386109A1
Authority
EP
European Patent Office
Prior art keywords
bone
csf
treatment
stimulators
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP88910226A
Other languages
German (de)
French (fr)
Inventor
Hugh E. Black
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of EP0386109A1 publication Critical patent/EP0386109A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to the acceleration of bone formation with GM-CSF.
  • Osteoporosis is responsible for at least 1.2 million fractures in the United States each year; it is responsible for more than 25,000 deaths annually; and it is estimated to have direct and indirect costs each year of $6.1 billion in the United States alone [Melton et al., The Osteoporotic Syndrome, Grune and Stratton, New York: 45-72 (1983); Cummings et al., Epidemiol. Rev. 7:178 (1985); Riggs et al., New Eng. J. Med. 314:1676 (1986)]. The disease is characterized by osteopenia and fractures.
  • Empirical treatment is usually aimed at decreasing bone resorption and/or increasing the production of new bone, thereby lessening the net degeneration of skeletal integrity.
  • Oral calcium supplements and sex hormones seem to decrease bone resorption.
  • a number of other treatments have been tried. These treatments, the possible causes of osteoporosis and the various manifestations of the disease are discussed by Riggs et al., New Eng. J. Med. 314:1676 (1986), which is hereby incorporated by reference.
  • Another aspect of the invention relates to treating mammals for bone fractures, particularly those which fail to unite, where so-called "non-unions" occur. Stimulation of mesenchymal cells from around the fracture site is required in cases of fractures where non-unions occur. In non-unions, there does not appear to be a proper stimulation signal to the mesenchymal cells to start callus formation after a fracture occurs. The formation of callus with development of the trabeculae of woven bone that has an accompanying marrow component is an important aspect of the bone-healing process.
  • Bone-morphogenic protein is a group of proteins existing in bone matrix and intimately associated with collagen fibrils. Isolation and characterization are difficult because BMP exists in its natural state in the hard bone matrix, but U.S.P. 4,761,471 (granted August 2, 1988) describes the isolation and substantial purification of bone morphogenic protein (which it terms 'Bone Morphogenetic Protein'). It has however been reported that solubilizing the matrix seems to alter the protein; Urist et al., J. Dent. Res. Suppl. No. 6, 50:1392 (1971); Urist et al., Cell Biology 76(4):1828 (1979).
  • Granulocyte macrophage colony stimulating factor is a lymphokine that stimulates the proliferation of a variety of undifferentiated precursor cells.
  • GM-CSF Granulocyte macrophage colony stimulating factor
  • One aspect of this invention involves treating mammals diagnosed as having osteoporosis.
  • the invention involves a method of treating such mammals by admin istering to them an effective anti-osteoporotic amount of a granulocyte macrophage colony stimulating factor (GM-CSF).
  • GM-CSF granulocyte macrophage colony stimulating factor
  • the mammals treated will be humans and the GM-CSF used will be one of the human allotypes. More preferably, administration of the human GM-CSF (hGM-CSF) will initially be daily to reestablish a normal bone-remodeling rate and later be periodical to maintain a normal bone-remodeling rate.
  • hGM-CSF human GM-CSF
  • the dosage for mammals will be about 1 to 300 ⁇ g of GM-CSF per kg of body weight per day. More preferably the dosage for humans will be about 2 to 10 ⁇ g of hGM-CSF per kg of body weight per day.
  • Another aspect of the invention involves administering an effective callus-forming amount of GM-CSF to stimulate mesenchymal stem cells around a fracture site to start callus formation, which is an important prerequisite to the bone-healing process.
  • Another aspect of the invention involves pharmaceutical combinations of GM-CSF and other stimulators of bone formation or inhibitors of bone resorption.
  • the invention provides a method for treating mammals diagnosed as having the disease osteoporosis by administering an effective anti-osteoporotic amount of a granulocyte macrophage colony stimulating factor (GM-CSF). Typically, the treatment will continue for a number of days and at a frequency necessary to maintain about normal bone-remodeling rate.
  • GM-CSF granulocyte macrophage colony stimulating factor
  • GM-CSF Any suitable GM-CSF may be employed in the present invention.
  • Complementary DNAs (cDNAs) for GM-CSF have recently been cloned and sequenced by a number of laboratories: e.g. Gough et al., Nature 309:763 (1984) (mouse); Lee et al., Proc. Natl. Acad. Sci 82:4360 (1985) (human); Wong et al., Science 228:810 (1985) (human and gibbon); Cantrell et al., Proc. Natl. Acad. Sci, 82:6250 (1985) (human).
  • non-recombinant GM-CSF has been purified from various culture supernatants: e.g.
  • mammals with osteoporosis are administered an effective anti-osteoporotic amount of a GM-CSF.
  • an amount is used sufficient to reestablish bone-remodeling rates to about normal and maintain them at about normal.
  • From about 1 to about 300 ⁇ g of human GM-CSF (hGM-CSF) per kg of body weight per day is preferably administered.
  • osteoporotic mammals e.g. humans
  • osteoporotic humans are administered 2 to 10 ⁇ g of hGM-CSF per kg of body weight per day.
  • the amount, frequency and period of administration will vary depending upon factors such as severity of the disease, age of the patient, activity of the patient, nutrition, etc. Usually, the administration will initially be daily and later be less frequent, and it may continue periodically during the remainder of the patient's lifetime. Dosage amount and frequency may be determined during initial screenings of bone-remodeling rate and the magnitude of the effect of GM-CSF upon the remodeling rate for specific patients. Dosage will be aimed at returning remodeling rate to as near normal as possible.
  • Administration of the dose may be intravenous, nasal, parental, oral, subcutaneous, intramuscular, topical, transdermal or by any other accepted method.
  • Such administration may be by pulse dosing, such as administration for 3 to 7 days followed by periods of rest without further drug administration, or further ('second') dosing etc.
  • Bone formation can be stimulated, for example, by administration of sodium fluoride, parathyroid hormone, prostaglandins, thyroxin, bone-morphogenic protein and high-phosphate diet. Bone resorption can be inhibited, for example, by administration of diphosphonates, calcitonin, glucocorticoids and high-calcium diet.
  • bone- formation stimulators and bone-resorption inhibitors are well known to those skilled in the art. In the present invention, their use will be in pharmaceutical combination with the GM-CSF or in combination with a compatible GM-CSF as part of the dosage regimen. These stimulators and inhibitors may or may not be combined with every administration of GM-CSF. The timing and amount of administration will be determined by the effect of specific stimulators and inhibitors on the events occurring during bone reformation.
  • GM-CSF GM-CSF on remodeling rates
  • test protocol which is well known to those skilled in the art as a method of determining the effects of a given dosage regimen for a drug on increasing bone-remodeling rates:
  • GM-CSF is administered at a defined dosage level and regimen for several weeks or months. This is followed by administration of another bone-labeling compound, DCAF.
  • DCAF is a fluorochrome label [(2,4 bis)N,N'-di(carboxymethyl)(aminomethylfluoroescein)], which can be obtained from ICN Pharmaceuticals, Inc.
  • Tetracycline which fluoresces green
  • DCAF which fluoresces red
  • Fluorescence is determined in bone cross-sections obtained from bone biopsies conducted before treatment with GM-CSF and after treatment with GM-CSF and DCAF. Entire rib cross-sections are obtained in biopsies conducted in monkeys, whereas iliac crest biopsy is the preferred method for obtaining bone cross-sections in humans.
  • the mean number was expressed per mm' of cortical area (A C ).
  • An osteoid seam was identified as a bone formation site by a green or red intimal band on sections stained with osteochrome.
  • ⁇ f represents the number of new csteons introduced per year in an average mm 2 of cortical area.
  • V f (A f ) X (S f ) X (M F )
  • Statistical significance of differences in the morphometric data comparing treatment effects between GM-CSF-dosed bone samples and control bone samples are determined by the Nemenyl Rank Sum One-Way Classification test of Dixon et al., Biomedical Computer Programs: P-Series, BMDT 77:603-652 (University of California-Berkeley Press) (1977), which is hereby incorporated by reference.
  • the invention also provides a method for treating mammals with fractures by stimulating mesenchymal stem cells with GM-CSF.
  • GM-CSF is used to activate the mesenchymal cells around the fracture site and thereby stimulate them to produce callus. Callus formation leads to development of trabeculae and accompanying bone marrow.
  • the GM-CSF is administered systemically or locally in sufficient amounts to induce the formation of callus.
  • Systemic and local administration are methods known to one skilled in the art.
  • Systemic administration indicates any means of introducing the pharmaceutical composition into the blood stream, including intraveneous, parental, subcutaneous, intramuscular, oral, nasal, topical and transdermal.
  • the pharmaceutical composition is applied directly to the vicinity of the cells to be affected, which here are the cells adjacent to the fracture area.
  • Such administration includes injections or surgically applied dosages.
  • One successful application of bone morphogenic protein is to surgically apply a capsule or other slowly-dissolving or sustained-released dosage directly to the fracture area. The amount, frequency and method of administration will depend upon the extent of non-union in the fracture.
  • the GM-CSF is human GM-CSF.
  • the positive effect of GM-CSFs on bone reformation can be enhanced when used in combination with other compounds.
  • Such stimulators of bone reformation include the same bone-formation stimulators and bone-resorption inhibitors as are discussed above.
  • the bone- formation stimulators including sodium fluoride, parathyroid hormone, prostaglandins, thyroxin, bone- morphogenic protein, local electrical stimulation and high-phosphate diet, are administered. In this aspect of the invention, their use will be in pharmaceutical combination with the GM-CSF or in combination with the GM-CSF as part of the dosage regimen. These stimulators and/or inhibitors may or may not be combined with every administration of GM-CSF.
  • the effect of GM-CSF on bone formation can be determined by the following test protocols, which are well known to those skilled in the art as a method of determining the effect of a given dosage regimen of a drug on increasing callus formation:
  • the effect of GM-CSF on bone formation is determined by studying the fracture-healing process over time.
  • the initial effect of GM-CSF upon the stimulation of mesenchymal cells around the new fracture site is determined by the incorporation of tritiated thymidine into nuclei of newly generated cells at the fracture site.
  • This technique applied over the first week of the study, uses autoradiography as the method to determine the rate of generation of new cells, as stimulated by GM-CSF.
  • Further study of the fracture-healing process uses the sequential microscopic evaluation of callus formation using undercalcified tissue sections collected from animals sacrificed at selected intervals after fracture. The sections are stained for fibrous stroma or mineralized callus.
  • the amount of fibrous stroma as well as the mineralized component of the callus is quantitated using quantitative image analysis.
  • polarized light microscopy is used to evaluate the morphologic character of the callus and to detect the presence or absence of union across the opposing edges of the shaft of the bone.
  • the fracture-healing process is further followed by the use of sequential x-rays on live animals.
  • the quality of the callus after approximately six weeks is determined by the application of measured mechanical forces to the fracture site in both tension and flexure. The breaking strength is thereby determined.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Sont décrits des procédés et des compositions accélérant la formation osseuse, utilisant les facteurs de croissance des colonies de granulocytes et de monocytes (GM-CSF). Les procédés comprennent des traitements pour l'ostéoporose et les fractures osseuses. Les compositions comprennent des GM-CSF en combinaison avec des stimulateurs de formation osseuse et/ou des inhibiteurs de résorption osseuse.Methods and compositions for accelerating bone formation using granulocyte and monocyte colony growth factors (GM-CSF) are described. The methods include treatments for osteoporosis and bone fractures. The compositions include GM-CSF in combination with bone formation stimulators and / or bone resorption inhibitors.

Description

ACCELERATION OF BONE FORMATION WITH GM-CSF
BACKGROUND OF THE INVENTION
This invention relates to the acceleration of bone formation with GM-CSF.
One aspect of this invention relates to treating the degenerative bone disease known as osteoporosis. Osteoporosis is responsible for at least 1.2 million fractures in the United States each year; it is responsible for more than 25,000 deaths annually; and it is estimated to have direct and indirect costs each year of $6.1 billion in the United States alone [Melton et al., The Osteoporotic Syndrome, Grune and Stratton, New York: 45-72 (1983); Cummings et al., Epidemiol. Rev. 7:178 (1985); Riggs et al., New Eng. J. Med. 314:1676 (1986)]. The disease is characterized by osteopenia and fractures.
The underlying problem, separate from the osteopenia, is a very slow remodeling rate in the cortical and trabecular bone. Remodeling is the turnover of bone tissue resulting from the linked processes of bone resorption and bone formation. Bone resorption is mediated by osteoclastic cells, which are derived from stem cell progenitors. Bone formation is thought to be mediated by osteoblastic cells, which are derived from mesenchyme cell progenitors. Both stem cells and mesenchyme cells are produced in bone marrow and may themselves have a common lineage. In the normal adult, these two processes are nearly equal, absolute bone loss is minimal and the remodeling (bone turnover) rate is six to nine months. The osteoporotic skeleton often requires two years or more for remodeling to occur. As a result of this slow remodeling process, microfractures in the reduced bone mass are only slowly repaired and occasionally progress to become major fractures. The primary complications of the disease are crush fractures of the vertebrae (which consist primarily of trabecular bone) and fractures of the neck of the femur and distal end of the radius (which consist of both cortical and trabecular bone).
Although the etiology of the disease is unknown, it is probably multifactorial. Empirical treatment is usually aimed at decreasing bone resorption and/or increasing the production of new bone, thereby lessening the net degeneration of skeletal integrity. Oral calcium supplements and sex hormones seem to decrease bone resorption. Administration of thyroxin, or feeding diets that are high in phosphorus and low in calcium for a period of time, seems to stimulate the bone-formation process. A number of other treatments have been tried. These treatments, the possible causes of osteoporosis and the various manifestations of the disease are discussed by Riggs et al., New Eng. J. Med. 314:1676 (1986), which is hereby incorporated by reference.
Another aspect of the invention relates to treating mammals for bone fractures, particularly those which fail to unite, where so-called "non-unions" occur. Stimulation of mesenchymal cells from around the fracture site is required in cases of fractures where non-unions occur. In non-unions, there does not appear to be a proper stimulation signal to the mesenchymal cells to start callus formation after a fracture occurs. The formation of callus with development of the trabeculae of woven bone that has an accompanying marrow component is an important aspect of the bone-healing process.
At present, the standard method of stimulating fracture non-union sites is surgery and either pinning or plating. Recently, non-union fractures have been treated with an experimental material called bone-morphogenic protein (BMP), which is placed surgically at the site of the non-union to stimulate local bone formation. Bone-morphogenic protein is a group of proteins existing in bone matrix and intimately associated with collagen fibrils. Isolation and characterization are difficult because BMP exists in its natural state in the hard bone matrix, but U.S.P. 4,761,471 (granted August 2, 1988) describes the isolation and substantial purification of bone morphogenic protein (which it terms 'Bone Morphogenetic Protein'). It has however been reported that solubilizing the matrix seems to alter the protein; Urist et al., J. Dent. Res. Suppl. No. 6, 50:1392 (1971); Urist et al., Cell Biology 76(4):1828 (1979).
Granulocyte macrophage colony stimulating factor (GM-CSF) is a lymphokine that stimulates the proliferation of a variety of undifferentiated precursor cells. Various cellular components of the bone marrow are stimulated to proliferate by GM-CSF: MacDonald et al., J. Bone Mineral Res., 1(2):227 (1986); Begley et al., Exp. Hematol., 13:956 (1985).
SUMMARY OF THE INVENTION
One aspect of this invention involves treating mammals diagnosed as having osteoporosis. The invention involves a method of treating such mammals by admin istering to them an effective anti-osteoporotic amount of a granulocyte macrophage colony stimulating factor (GM-CSF). Such an effective amount would reestablish and maintain bone-remodeling rates that are about normal.
Preferably, the mammals treated will be humans and the GM-CSF used will be one of the human allotypes. More preferably, administration of the human GM-CSF (hGM-CSF) will initially be daily to reestablish a normal bone-remodeling rate and later be periodical to maintain a normal bone-remodeling rate.
Preferably, the dosage for mammals will be about 1 to 300 μg of GM-CSF per kg of body weight per day. More preferably the dosage for humans will be about 2 to 10μg of hGM-CSF per kg of body weight per day.
Another aspect of the invention involves administering an effective callus-forming amount of GM-CSF to stimulate mesenchymal stem cells around a fracture site to start callus formation, which is an important prerequisite to the bone-healing process.
Another aspect of the invention involves pharmaceutical combinations of GM-CSF and other stimulators of bone formation or inhibitors of bone resorption.
Detailed Description
The invention provides a method for treating mammals diagnosed as having the disease osteoporosis by administering an effective anti-osteoporotic amount of a granulocyte macrophage colony stimulating factor (GM-CSF). Typically, the treatment will continue for a number of days and at a frequency necessary to maintain about normal bone-remodeling rate.
Any suitable GM-CSF may be employed in the present invention. Complementary DNAs (cDNAs) for GM-CSF have recently been cloned and sequenced by a number of laboratories: e.g. Gough et al., Nature 309:763 (1984) (mouse); Lee et al., Proc. Natl. Acad. Sci 82:4360 (1985) (human); Wong et al., Science 228:810 (1985) (human and gibbon); Cantrell et al., Proc. Natl. Acad. Sci, 82:6250 (1985) (human). Moreover, non-recombinant GM-CSF has been purified from various culture supernatants: e.g. U.S. Patent 4,438,032 (Mo cell line); Burgers et al., Exp. Hematol. 9:893 (1981) (mouse); Sparrow et al., Proc. Natl. Acad. Sci., 82:292 (1985) (purification and partial amino acid sequence for mouse); Wu et al., Exp. Hematol., 12:267 (1984) (rat); Gasson et al., Science 226:1339 (1984) (human); Sieff et al., Science 230:1171 (1985) (human); Burgess et al., Blood, 69:43 (1987) (human). Among the human GM-CSFs, heterogeneity in the sequences of the nucleotides and of the amino acids has been observed. For example, at the amino acid level of hGM-CSF both threonine and isoleucine have been observed at position 100 with respect to the N-terminal alanine, suggesting that allelic forms, or polymorphs, of GM-CSF may exist within human populations. Also, various leader sequences occur at the N-terminal portion of the amino acid sequence. These leaders may be of various lengths and amino acid composition, which may or may not affect biological activity. All of the above discussed references are incorporated herein by reference for their disclosures of representative GM-CSFs suitable for use in the present invention.
According to this invention, mammals with osteoporosis are administered an effective anti-osteoporotic amount of a GM-CSF. Preferably, an amount is used sufficient to reestablish bone-remodeling rates to about normal and maintain them at about normal. From about 1 to about 300 μg of human GM-CSF (hGM-CSF) per kg of body weight per day is preferably administered. More preferably, osteoporotic mammals (e.g. humans) are administered 1 to 100 μg of GM-CSF (e.g. hGM-CSF) per kg of body weight per day. Most preferably, osteoporotic humans are administered 2 to 10 μg of hGM-CSF per kg of body weight per day.
The amount, frequency and period of administration will vary depending upon factors such as severity of the disease, age of the patient, activity of the patient, nutrition, etc. Usually, the administration will initially be daily and later be less frequent, and it may continue periodically during the remainder of the patient's lifetime. Dosage amount and frequency may be determined during initial screenings of bone-remodeling rate and the magnitude of the effect of GM-CSF upon the remodeling rate for specific patients. Dosage will be aimed at returning remodeling rate to as near normal as possible.
Administration of the dose may be intravenous, nasal, parental, oral, subcutaneous, intramuscular, topical, transdermal or by any other accepted method. Such administration may be by pulse dosing, such as administration for 3 to 7 days followed by periods of rest without further drug administration, or further ('second') dosing etc.
Since bone reformation is a sequential mechanism with multifactoral regulation, it is likely that the positive effect of GM-CSFs on bone remodeling can be enhanced when these are used in combination with other compounds. Such stimulators of bone remodeling include bone-formation stimulators and bone-resorption inhibitors. This invention encompasses such pharmaceutical combinations. Bone formation can be stimulated, for example, by administration of sodium fluoride, parathyroid hormone, prostaglandins, thyroxin, bone-morphogenic protein and high-phosphate diet. Bone resorption can be inhibited, for example, by administration of diphosphonates, calcitonin, glucocorticoids and high-calcium diet. The availability, source, activity, effect and use of these and other bone- formation stimulators and bone-resorption inhibitors are well known to those skilled in the art. In the present invention, their use will be in pharmaceutical combination with the GM-CSF or in combination with a compatible GM-CSF as part of the dosage regimen. These stimulators and inhibitors may or may not be combined with every administration of GM-CSF. The timing and amount of administration will be determined by the effect of specific stimulators and inhibitors on the events occurring during bone reformation.
The effect of GM-CSF on remodeling rates can be determined by the following test protocol, which is well known to those skilled in the art as a method of determining the effects of a given dosage regimen for a drug on increasing bone-remodeling rates:
Patients are dosed with tetracycline one to three weeks prior to treatment with the GM-CSF. Tetracycline may be administered in a single dose or in several repeated doses. GM-CSF is administered at a defined dosage level and regimen for several weeks or months. This is followed by administration of another bone-labeling compound, DCAF. DCAF is a fluorochrome label [(2,4 bis)N,N'-di(carboxymethyl)(aminomethylfluoroescein)], which can be obtained from ICN Pharmaceuticals, Inc.
Tetracycline, which fluoresces green, and DCAF, which fluoresces red, are both incorporated into newly forming bone-fronts. Therefore, if tetracycline is administered to a mammal with a fracture, and DCAF is later administered, an examination of a section of the healing fracture will provide information about the bone- remodeling rate. If parallel experiments are done upon different mammals, some of which are administered GM-CSF, and some of which receive no GM-CSF, then the said measurement and comparison will provide information about the relative bone-remodeling rates in the presence of GM-CSF and in its absence.
Fluorescence is determined in bone cross-sections obtained from bone biopsies conducted before treatment with GM-CSF and after treatment with GM-CSF and DCAF. Entire rib cross-sections are obtained in biopsies conducted in monkeys, whereas iliac crest biopsy is the preferred method for obtaining bone cross-sections in humans.
Once the bone cross-sections are obtained, the following nine measurements and counts are obtained for cortical bone:
(1) Cortical area (AC)
(2) Total area (AT)
(3) Total number of osteoid seams (Af)
The mean number was expressed per mm' of cortical area (AC). An osteoid seam was identified as a bone formation site by a green or red intimal band on sections stained with osteochrome.
(4) Total number of resorption cavities (Ar)
Measured by systematic scanning of the entire section using a 10 X objective. Resorption cavities were identified by the presence of scalloped edges.
(5) Total number of labelled osteoid seams (L)
(6) Mean distance between fluorochrome dyes within a single Haversian system (MAR)
(7) Mean wall thickness of finished osteons (MWT)
(8) Osteoid seam thickness (OST)
(9) Mean circumference of osteoid seams (Sf)
From the nine basic measurements, the quantitative morphometric analysis of bone consists of the following stereological calculations disclosed by Frost, Bone Remodeling and Its Relationship to Metabolic Bone Diseases, Orthopedic Lectures, Vol. Ill, Charles Thomas Publisher, (1973), which is hereby incorporated by reference:
(1) Total Cortical Cross Sectional Area (AC) ιn mm2
(2) Total Cross Sectional Area (AT) in mm2
( "Hits " and "throws " are well-understood terms of a scoring system used to determine cross- section on a microscopic grid ; they are also described in the Frost reference immediately above.) (3) Mean Number of Osteoid Seams per mm2
(Af)
(4) Mean Number of Resorption Cavities per mm2 (Ar)
(5) Percent labelled Osteoid Seams (%L)
(6) Mean Appositional Rate (M) in μ/day
.(7) Radial Closure Rate (Mf) in mm/yr.
Mf = (M) X (%L) X (365/1000*)
*reduces microns /day to mm/year
(8) Osteoid Seam Circumference (Sf)
(9) Ratio of Cortical (C) Area in mm2 (Ac) to Total (T)
Area in mm2 (AT)
(10) Ratio of the Numbers of Resorption Cavities (Ar) to Osteoid Seams (Af) Ar/Af
(11) Osteon Formation time in Years (Of)
The time required to complete lamellar bone formation in a cross section of an average osteon.
(12) Number of Activation Frequency Foci in mm /year
(μf)
μf represents the number of new csteons introduced per year in an average mm2 of cortical area.
(13) Bone Formation Rate in mm2 of new bone per mm2 of existing bone surface per year (Vf)
Vf = (Af) X (Sf) X (MF) Statistical significance of differences in the morphometric data comparing treatment effects between GM-CSF-dosed bone samples and control bone samples are determined by the Nemenyl Rank Sum One-Way Classification test of Dixon et al., Biomedical Computer Programs: P-Series, BMDT 77:603-652 (University of California-Berkeley Press) (1977), which is hereby incorporated by reference.
The invention also provides a method for treating mammals with fractures by stimulating mesenchymal stem cells with GM-CSF. GM-CSF is used to activate the mesenchymal cells around the fracture site and thereby stimulate them to produce callus. Callus formation leads to development of trabeculae and accompanying bone marrow.
The GM-CSF is administered systemically or locally in sufficient amounts to induce the formation of callus. Systemic and local administration are methods known to one skilled in the art. Systemic administration indicates any means of introducing the pharmaceutical composition into the blood stream, including intraveneous, parental, subcutaneous, intramuscular, oral, nasal, topical and transdermal. In local administration, the pharmaceutical composition is applied directly to the vicinity of the cells to be affected, which here are the cells adjacent to the fracture area. Such administration includes injections or surgically applied dosages. One successful application of bone morphogenic protein is to surgically apply a capsule or other slowly-dissolving or sustained-released dosage directly to the fracture area. The amount, frequency and method of administration will depend upon the extent of non-union in the fracture. Preferably, the GM-CSF is human GM-CSF. As with the treatment of osteoporosis with GM- CSF, the positive effect of GM-CSFs on bone reformation can be enhanced when used in combination with other compounds. Such stimulators of bone reformation include the same bone-formation stimulators and bone-resorption inhibitors as are discussed above. Preferably, the bone- formation stimulators, including sodium fluoride, parathyroid hormone, prostaglandins, thyroxin, bone- morphogenic protein, local electrical stimulation and high-phosphate diet, are administered. In this aspect of the invention, their use will be in pharmaceutical combination with the GM-CSF or in combination with the GM-CSF as part of the dosage regimen. These stimulators and/or inhibitors may or may not be combined with every administration of GM-CSF.
The effect of GM-CSF on bone formation can be determined by the following test protocols, which are well known to those skilled in the art as a method of determining the effect of a given dosage regimen of a drug on increasing callus formation:
The effect of GM-CSF on bone formation is determined by studying the fracture-healing process over time. The initial effect of GM-CSF upon the stimulation of mesenchymal cells around the new fracture site is determined by the incorporation of tritiated thymidine into nuclei of newly generated cells at the fracture site. This technique, applied over the first week of the study, uses autoradiography as the method to determine the rate of generation of new cells, as stimulated by GM-CSF. Further study of the fracture-healing process uses the sequential microscopic evaluation of callus formation using undercalcified tissue sections collected from animals sacrificed at selected intervals after fracture. The sections are stained for fibrous stroma or mineralized callus. The amount of fibrous stroma as well as the mineralized component of the callus is quantitated using quantitative image analysis. In addition, polarized light microscopy is used to evaluate the morphologic character of the callus and to detect the presence or absence of union across the opposing edges of the shaft of the bone. After approximately two weeks the fracture-healing process is further followed by the use of sequential x-rays on live animals. Finally, the quality of the callus after approximately six weeks is determined by the application of measured mechanical forces to the fracture site in both tension and flexure. The breaking strength is thereby determined.

Claims

CLAIMS :
1. A method for treating a mammal diagnosed as having osteoporosis comprising administering to said mammal an effective anti-osteoporotic amount of a granulocyte macrophage colony stimulating factor (GM-CSF).
2. The method of treatment of claim 1 wherein said GM-CSF is administered in an amount of about 1 to about 300 μg per kg of body weight per dose.
3. The method of treatment of claim 1 wherein said GM-CSF is human GM-CSF.
4. The method of treatment of claim 3 wherein said human GM-CSF is administered in an amount of about 1 to about 10 μg per kg of body weight per dose.
5. The method of treatment of claim 4 wherein the mode of administration is selected from the group consisting of intravenous, parental, subcutaneous, intramuscular, oral, nasal, topical and transdermal.
6. The method of treatment of claim 4 wherein the mode of administration is nasal or oral.
7. The method of treatment of claim 4 wherein the mode of administration is topical or transdermal.
8. The method of treatment of claim 4 wherein the mode of administration is intravenous, parental, subcutaneous or intramuscular.
9. The method of treatment of claim 4 wherein said dose is administered about daily until the bone-remodeling rate is about normal and at a frequency thereafter to maintain about a normal bone-remodeling rate.
10. The method of treatment of claim 1 further comprising administration of GM-CSF in combination with one or more stimulators of the bone-reformation process in an effective amount to reestablish and maintain bone-remodeling rates at about normal.
11. The method of treatment of claim 10 wherein said GM-CSF is human GM-CSF.
12. The method of treatment of claim 11 wherein said stimulators of the bone-reformation process are selected from the group consisting of bone-formation stimulators and bone-resorption inhibitors.
13. The method of treatment of claim 12 wherein said bone-formation stimulators are selected from the group consisting of sodium fluoride, parathyroid hormone, prostaglandins, thyroxin, bone-morphogenic protein and high-phosphate diet.
14. The method of treatment of claim 13 wherein said bone-resorption inhibitors are selected from the group consisting of diphosphonates, calcitonin, glucocorticoids and high-calcium diet.
15. A method for treating mammalian bone fractures comprising administering to said mammal an effective callus-forming amount of a granulocyte macrophage colony stimulating factor (GM-CSF) to stimulate callus formation.
16. The method of treatment of claim 15 wherein the mode of administration is systemic.
17. The method of treatment of claim 15 wherein the mode of administration is local.
18. The method of treatment of claim 15 further comprising administering GM-CSF in combination with one or more stimulators of the bone-reformation process in an effective amount to stimulate production of callus.
19. A pharmaceutical composition comprising an effective amount of GM-CSF, said amount selected from an effective anti-osteoporotic amount and an effective callus-forming amount, in combination with one or more stimulators of the bone-reformation process.
20. The pharmaceutical composition of claim 19 wherein said GM-CSF is human GM-CSF.
21. The pharmaceutical composition of claim 20 wherein said stimulators of the bone-reformation process are selected from the group consisting of bone-formation stimulators and bone-resorption inhibitors.
22. The pharmaceutical composition of claim 21 wherein said bone-formation stimulators are selected from the group consisting of sodium fluoride, parathyroid hormone, prostaglandins, thyroxin, bone-morphogenic protein, local electrical stimulation and high-phosphate diet.
23. The pharmaceutical composition of claim 21 wherein said bone-resorption inhibitors are selected from the group consisting of diphosphonates, calcitonin, glucocorticoids and high-calcium diet.
EP88910226A 1987-11-12 1988-11-10 Acceleration of bone formation with gm-csf Pending EP0386109A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11961187A 1987-11-12 1987-11-12
US119611 1987-11-12

Publications (1)

Publication Number Publication Date
EP0386109A1 true EP0386109A1 (en) 1990-09-12

Family

ID=22385326

Family Applications (2)

Application Number Title Priority Date Filing Date
EP88910226A Pending EP0386109A1 (en) 1987-11-12 1988-11-10 Acceleration of bone formation with gm-csf
EP88310594A Withdrawn EP0318184A1 (en) 1987-11-12 1988-11-10 Acceleration of bone formation with GM-CSF

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP88310594A Withdrawn EP0318184A1 (en) 1987-11-12 1988-11-10 Acceleration of bone formation with GM-CSF

Country Status (6)

Country Link
EP (2) EP0386109A1 (en)
JP (1) JPH0649655B2 (en)
AU (1) AU638204B2 (en)
DK (1) DK116390A (en)
IL (1) IL88344A (en)
WO (1) WO1989004173A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178855A (en) * 1989-01-30 1993-01-12 Schering Corporation Treatment of luekocyte dysfunction with GM-CSF
NZ236618A (en) * 1990-01-03 1997-06-24 Ciba Geigy Ag Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound
US5206023A (en) * 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
JPH0517367A (en) * 1991-07-08 1993-01-26 Green Cross Corp:The Treating agent for osteoporosis
US5270300A (en) * 1991-09-06 1993-12-14 Robert Francis Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone
ES2215359T3 (en) * 1991-12-18 2004-10-01 Icu Medical, Inc. FLUID TRANSFER PROCEDURE.
TW267102B (en) 1992-03-13 1996-01-01 Ciba Geigy
EP0891779A1 (en) * 1997-06-19 1999-01-20 Roche Diagnostics GmbH Pharmaceutical combinations containing parathyroid hormone and calcium and/or phosphor compounds
SE9702401D0 (en) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
JP4709440B2 (en) * 2001-08-20 2011-06-22 高山産業株式会社 Spacer for forming air passage and method for forming air passage in wall using the spacer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR893138A (en) * 1940-04-05 1944-05-31 Process for preparing a product for healing bone fractures
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
DE3545568A1 (en) * 1985-12-21 1987-07-16 Hoechst Ag GM-CSF-PROTEIN, ITS DERIVATIVES, PRODUCTION OF SUCH PROTEINS AND THEIR USE
AU626530B2 (en) * 1987-07-17 1992-08-06 Schering Biotech Corporation Human granulocyte-macrophage colony stimulating factor and muteins thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8904173A1 *

Also Published As

Publication number Publication date
IL88344A (en) 1994-06-24
WO1989004173A1 (en) 1989-05-18
DK116390D0 (en) 1990-05-10
JPH02502642A (en) 1990-08-23
EP0318184A1 (en) 1989-05-31
IL88344A0 (en) 1989-06-30
DK116390A (en) 1990-05-10
JPH0649655B2 (en) 1994-06-29
AU2710388A (en) 1989-06-01
AU638204B2 (en) 1993-06-24

Similar Documents

Publication Publication Date Title
Nakamura et al. Recombinant human basic fibroblast growth factor accelerates fracture healing by enhancing callus remodeling in experimental dog tibial fracture
US7638486B2 (en) Method for promoting hard tissue formation
Foster et al. Advances in defining regulators of cementum development and periodontal regeneration
Wang et al. Controlled-release of rhBMP-2 carriers in the regeneration of osteonecrotic bone
AU599031B2 (en) Regulation of degradation processes in bone
Wang et al. Thrombin peptide (TP508) promotes fracture repair by up‐regulating inflammatory mediators, early growth factors, and increasing angiogenesis
Guizzardi et al. Polydeoxyribonucleotide (PDRN) promotes human osteoblast proliferation: a new proposal for bone tissue repair
JPH09510209A (en) Use of fibroblast growth factor to stimulate bone growth
EP0386109A1 (en) Acceleration of bone formation with gm-csf
Lucas et al. Stimulation of systemic bone formation induced by experimental blood loss.
EP1313440B1 (en) Dental products comprising bone growth enhancing peptide
Bail et al. Recombinant species-specific growth hormone increases hard callus formation in distraction osteogenesis
Yao et al. CCL2 is a critical mechano-responsive mediator in crosstalk between osteoblasts and bone mesenchymal stromal cells
Schneider et al. The anabolic effects of vitamin D-binding protein-macrophage activating factor (DBP-MAF) and a novel small peptide on bone
Feng et al. Small blood stem cells for enhancing early osseointegration formation on dental implants: a human phase I safety study
WO2015057836A2 (en) Bone anabolic parathyroid hormone and parathyroid hormone related-protein analogs
CN111632147A (en) Application of bone cell Wnt activator in preparing medicine for accelerating fracture healing, preventing and treating bone nonunion and no movement or weightlessness bone loss
Drakopoulos et al. Off-label use of teriparatide in spine
Gandhi et al. Platelet releasate enhances healing in patients with a non-union
Yuli et al. Effect of Aloe vera gel on the expression of FGF-2, TGF-β, and Smad3 in the root surface of rat teeth after Traumatic avulsion
Laurina et al. Growth factors/cytokines/defensins and apoptosis in periodontal pathologies
Chunxiao et al. Pharmacological effects of a recombinant hPTH (1− 34) derived peptide on ovariectomized rats
Morshed et al. Fracture healing
JPH07504160A (en) bone regeneration
US20160220639A1 (en) Methods and compositions for treating bone diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 19900515

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

XX Miscellaneous (additional remarks)

Free format text: VERFAHREN ABGESCHLOSSEN INFOLGE VERBINDUNG MIT 88310594.2/0318184 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) VOM 24.04.91.